ASCO Updates Antiemetic Guidelines in Patients on Chemotherapy

Oncology Nurse Advisor reports that “the American Society of Clinical Oncology (ASCO) has updated their antiemetic guideline regarding the use of palonosetron and netupitant in combination to treat nausea and vomiting in patients receiving chemotherapy.” The update “committee recommends that patients receiving highly emetogenic chemotherapy regimens be offered a combination of a NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone, with netupitant and palonosetron plus dexamethasone (oral combination) also being an option for additional therapy.” Besides that, the “committee…did not recommend deviations from 2011 ASCO guideline at this time.”

The update is published in the Journal of Clinical Oncology.

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Navigation